Market ChallengesAPAP can be misdiagnosed with similar symptoms to pneumonia, bronchitis or asthma, resulting in delayed accurate diagnosis.
Regulatory RisksEven if manufacturing issues arise, SVRA has a backup plan with Fujifilm, suggesting that FDA approval is seen as a matter of time.
Sales UncertaintyManagement expects to identify 1,000 aPAP patients by launch, potentially representing $300M-$500M in annual sales.